Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $70.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]

Related Keywords

California ,United States ,Stephenf Betz ,Robertw Baird ,Richard Scott Struthers ,Janus Henderson Group ,Comerica Bank ,Artal Group ,Analyst Recommendations For Crinetics Pharmaceuticals ,Insider Activity At Crinetics Pharmaceuticals ,Securities Exchange Commission ,Investment Company Inc ,Crinetics Pharmaceuticals Company Profile ,Crinetics Pharmaceuticals ,Crinetics Pharmaceuticals Stock Performance ,Institutional Trading Of Crinetics Pharmaceuticals ,Cantor Fitzgerald ,News Ratings For Crinetics Pharmaceuticals Daily ,Crinetics Pharmaceuticals Inc ,Morgan Stanley ,Free Report ,Moderate Buy ,Get Free Report ,Scott Struthers ,Exchange Commission ,State Teachers Retirement System ,Henderson Group ,Crinetics Pharmaceuticals Daily ,